Report - Clinical Policy: Alirocumab (Praluent) · a) ≥ 190 mg/dL for genetically mediated primary hyperlipidemias; b) ≥ 220 mg/dL for non-genetically mediated primary hyperlipidemias;

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form